Shuttle Pharmaceuticals Appoints Industry Veteran George Scorsis As Chairman Of The Board

Shuttle Pharmaceuticals Holdings, Inc., a biopharmaceutical company advancing therapies to enhance radiation treatment outcomes for cancer patients, has appointed George Scorsis as Chairman of its Board of Directors. Scorsis has served as a director at Shuttle Pharma since February 2025 and brings decades of leadership experience across multiple regulated industries. Mr Scorsis has more than 25 years of executive experience in sectors such as alcohol, energy drinks, biotech, and cannabis. 

George Scorsis, newly appointed Chairman of the Shuttle Pharma Board of Directors, commented, “I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.”

He has also held leadership roles at several public and private companies, including President of Mettrum Health Corp., CEO and Director of Liberty Health Sciences, and Chairman of SOL Global Investments Corp. He currently holds chairmanships at Entourage Health Corp. and AWAKN Life Sciences, both traded on Canadian stock exchanges. His appointment signals Shuttle Pharma’s continued commitment to strengthening its leadership team as it moves forward in the development of novel radiation sensitizers.